How to Inject Tirzepatide: Sites, Syringes and Steps
Where to inject Tirzepatide, which syringe to use, how to read units and the hygiene steps that prevent infection.
Injection sites
Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.
- Belly: at least 2 inches (5 cm) away from the navel.
- Front and outer thighs.
- Back of the upper arms, if someone else can reach it.
- Rotate sites each time and avoid skin that is bruised, scarred or irritated.
Syringe and needle
U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Tirzepatide in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).
How to read an insulin syringeStep by step
- 1Wash your handsUse soap and water, and work on a clean surface.
- 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
- 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
- 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
- 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
- 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
Where the Mounjaro and Zepbound labels say to inject
Zepbound's label lists the abdomen and thigh for self-injection, and reserves the back of the upper arm for an injection given by another person. It also asks for a different site with each dose.[18]
Mounjaro's label gives the same sites: the abdomen, the thigh, or the back of the upper arm when another person injects.[19]
In its pharmacokinetics section, the Zepbound label reports similar exposure after injection in the abdomen, thigh or upper arm.[18]
Mounjaro's label says to give it with insulin as separate injections, never mixed, and that the same body region is acceptable if the injections are not adjacent.[19]
Pens, KwikPens and vials: the syringe instruction applies only to vials
Only the vial presentation involves drawing up a dose. The Zepbound label tells prescribers to supply a syringe sized for the dose and to use a fresh syringe and needle every time.[18]
The label's strengths table shows what a multi-dose vial contains: 2.5 mg in 0.6 mL per injection, 10 mg in 2.4 mL in total, at 4.17 mg per mL.[18]
On a U-100 syringe (100 units per mL), the labelled 0.6 mL injection volume reads as 60 units. 2.4 mL divided by 0.6 mL gives 4 injections per vial, matching the label.
Calculated from labelled injection volume m L 0.6; vial volume m L 2.4; U100 units per m L 100. Formula: 0.6 x 100 = 60 units; 2.4 / 0.6 = 4
Mounjaro's label puts a clock on opened multi-dose vials and KwikPens: discard after 30 days from first use or after the 4 weekly doses, whichever comes first.[19]
Timing windows and injection-site reactions in the labels
Zepbound's patient text lets the weekly day change if at least 3 days (72 hours) separate consecutive doses, and says to take a missed dose within 4 days (96 hours).[18]
In the Zepbound trial table, injection-site reactions were 2% in the placebo column and 6%, 8% and 8% in the three ascending-dose columns.[18]
In Mounjaro's pooled placebo-controlled trials in adults, injection site reactions were reported in 3.2% of treated patients and 0.4% of placebo patients.[19]
Vials sold outside the brand products
FDA's page states that a multi-dose vial should be discarded within 28 days of first use even if medication remains, even where the compounder says longer is acceptable, and that each dose needs a new, sterile needle and syringe.[20]
Common questions
Where do you inject Tirzepatide?
Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.
What syringe is used for Tirzepatide?
Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.
How often is Tirzepatide injected?
The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.
Where is the best place to inject Zepbound?
The label lists the abdomen, the thigh and, with another person's help, the back of the upper arm, and reports similar exposure from the three.[18]
Can you inject Mounjaro into the same spot each week?
No. The label asks for rotation with each dose.[19]
Can Mounjaro be injected at the same time as insulin?
The label allows Mounjaro and insulin in the same body region as separate injections that are not adjacent and never mixed.[19]
More on Tirzepatide
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt] (93 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular) (410 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt] (24 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: tirzepatide[ti] AND (steatohepatitis OR "heart failure" OR "SUMMIT" OR "SYNERGY-NASH" OR "phase 2") AND randomized controlled trial[pt] (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: tirzepatide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR glycemic OR HbA1c OR obesity) (178 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: tirzepatide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (49 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: tirzepatide[ti] AND (insulin degludec OR "SURPASS-3") AND "type 2 diabetes"[ti] AND randomized controlled trial[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: tirzepatide[ti] AND (cardiovascular outcomes OR "SURPASS-CVOT" OR "major adverse") (228 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: tirzepatide[tiab] AND (depression OR anxiety OR ADHD OR osteoporosis OR "bone mineral" OR menopause OR "rheumatoid" OR arthritis OR testosterone) (121 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: tirzepatide[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "visceral fat"[tiab] OR "fat mass"[tiab]) AND humans[mh] (91 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: tirzepatide[tiab] AND (blood pressure[tiab] OR cholesterol[tiab] OR lipid*[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: tirzepatide[tiab] AND (SURPASS-CVOT OR "cardiovascular events" ) AND "dulaglutide"[tiab] AND randomized controlled trial[pt] (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: tirzepatide[tiab] AND (depression[tiab] OR anxiety[tiab] OR "mental health"[tiab] OR ADHD[tiab] OR "binge eating"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: tirzepatide[tiab] AND (menopaus*[tiab] OR PCOS[tiab] OR "polycystic"[tiab] OR testosterone[tiab] OR hypogonadism[tiab]) (55 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 19MOUNJARO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 20Official web pageOfficial web page · web page
Found an error? Report a correction.